ÂÜÀòÂÒÂ×

Annette Ervin-Haynes is a seasoned professional in the pharmaceutical industry with extensive experience in oncology and drug development. Currently serving as the Vice President of Targeted Therapy at Servier, Annette has previously held key leadership roles such as Vice President and Head of Early Drug Development at ADC Therapeutics, and Vice President at Genmab. Additional experience includes positions as Executive Director of Clinical R&D Oncology and Medical Director at Celgene, as well as Senior Director at Imclone. Annette earned a Doctor of Osteopathic Medicine degree from Oklahoma State University School of Osteopathic Medicine and has educational background from the University of Hartford.